New Time Eligibility Announced for Byetta Pancreatic Cancer Allegation Cases Being Reviewed by Resource4thePeople Attorneys
National network of attorneys announces extended eligibility for complimentary consultations as more consumers inquire about their legal rights to seek compensation in wake of FDA announcement that it is investigating possible links between Byetta and other diabetes drugs and pancreatitis.
San Diego, CA (PRWEB) June 28, 2013
Resource4thePeople announced today extended time eligibilities for consumers who are seeking legal consultations over allegations that their use of a class of diabetes drug including Byetta may have caused them to suffer severe side effects of the pancreas.
"This announcement is being made in order to clarify the status of consumers who have been inquiring about their legal rights since the Food and Drug Administration's March 14, 2013 announcement* about its investigation into possible links between these medications and pancreatitis and cancer," said Resource4thePeople.
"Therefore, we are announcing that consumers who may have been using the medications before and after the announcement are both eligible to seek consultations with our national legal network."
Resource4thePeople is informing consumers that if they have any confusion about their status in possibly seeking compensation for alleged side effects they should take steps now to preserve their legal rights.
The complimentary consultations were offered in response to a large volume of inquiries from consumers triggered by the FDA's announcement that it is investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs such as Byetta for type 2 diabetes.
The FDA identified these drugs as exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto).
“There are a significant number of Americans who treat their diabetes with these medications and the FDA announcement has had widespread ramifications in terms of patients seeking information about their legal options,” said Resource4thePeople.
“As a result, our national legal network will continue to offer free legal consultations in which consumers may determine their eligibility to file a claim or lawsuit and seek compensation for the medical expenses, pain and suffering and other costs that may have been incurred.”
In its announcement, an FDA spokesman said that the findings were based on examination of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes.
The FDA has asked researchers to provide the methodology used to collect and study these specimens and to provide the tissue samples so the agency can further investigate potential pancreatic toxicity associated with the incretin mimetics.
Resource4thePeople notes that there may be legal time limits involved in such actions and is requesting consumers to make contact as soon as possible in order to preserve all legal options available.
Byetta was originally approved by the FDA and released onto the market in 2005, with its primary function being to help patients with diabetes manage their condition.
It is applied by injection and it and the other incretin mimetics, according to the FDA, mimic the incretin hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal.
The agency said the medications are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
In its announcement, the FDA reiterated a previous public warning “about postmarketing reports of acute pancreatitis, including fatal and serious nonfatal cases, associated with the use of incretin mimetic drugs exenatide and sitagliptin.”
An agency official also said that a recently published study that examined insurance records also found the use of exenatide or sitagliptin could double the risk of developing acute pancreatitis.
The official said that the Warnings and Precautions section of the drug labels and the patient Medication Guides for incretin mimetics contain warnings about the risk of acute pancreatitis.
Resource4thePeople also is providing consumers some of the cautionary analysis about Byetta and its sister drugs. Here are some of the warnings and precautions taken from the agency’s web site:**
What is the most important information I should know about BYETTA?
- Serious side effects can happen in people who take BYETTA, including inflammation of the pancreas (pancreatitis) which may be severe and lead to death.
Before taking BYETTA, tell your healthcare provider if you have had:
- stones in your gallbladder (gallstones).
- a history of alcoholism.
- high blood triglyceride levels.
These medical conditions can make you more likely to get pancreatitis in general. It is not known if having these conditions will lead to a higher chance of getting pancreatitis while taking BYETTA.
While taking BYETTA:
- Call your healthcare provider right away if you have pain in your stomach area (abdomen) that is severe, and will not go away. The pain may happen with or without vomiting. The pain may be felt going from your abdomen through to your back. These may be symptoms of pancreatitis.
Resource4thePeople also is recommending that consumers update themselves on media reports about the side effects, such as one recently posted by Bloomberg News about the research study and concerns about the safety of the medication as voiced by the FDA earlier and by physicians:***
“Doctors have been concerned that this category of diabetes treatments may damage the pancreas since the FDA said in 2007 it received a high number of reports of pancreatitis in patients taking Byetta.
“The agency issued a similar alert for Januvia in 2009. An analysis of insurance records published last month in the journal JAMA Internal Medicine showed such drugs may double a user’s risk of pancreatitis. That hasn’t stopped these medicines from becoming multibillion-dollar drugs.”
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/6/prweb10876467.htm